Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
|
|
- Ashlynn Tyler
- 6 years ago
- Views:
Transcription
1 Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Université de Lyon
2 From viral suppression to cure ccc-dna Liver Normal Cirrhosis Hepatocellular carcinoma Rc-DNA HBV-DNA UNTREATED Blood Normal Cirrhosis Hepatocellular carcinoma ccc-dna Liver Rc-DNA Blood NUCs Risk of HCC reduced (after 5 yrs) but not eliminated ccc-dna Liver Liver NMEs Cure NMEs Normal Cirrhosis Hepatocellular carcinoma Blood Blood Direct Antiviral Agents Immunomodulatory strategies Zoulim & Levrero
3 Is HBV Cure Possible? Can treatment accomplish what nature can t? HBV persists in persons who have recovered from acute hepatitis B with to anti-hbs seroconversion Reactivation of HBV replication can occur during potent immunosuppressive therapy Transmission of HBV is possible when these livers are transplanted Long-lasting rigorous immune response to HBV possibly from continued stimulation by residual virus
4 Barriers to eradicating HBV cccdna reservoir Long t1/2 Continuous replenishment Not affected by NAs and IFN Integrated forms HBV persistence Defective CD8+ responses Defective B cell responses Inefficient innate response Defective immune responses Locarnini, S. & Zoulim, F. et al. (2016) Global strategies are required to cure and eliminate HBV infectionnat. Rev. Gastroenterol. Hepatol.
5 Persistence of intrahepatic viral DNA synthesis during Tenofovir therapy (HIV-HBV cohort) New round of infection and/or replenishment of the cccdna pool occur despite «viral suppression» Boyd et al, J Hepatol 2016
6 Loss Decreases Subsequent Risk of HCC REVEAL study , no cirrhosis loss Hazard ratio for HCC after seroclearance during follow up HBeAg 0.63 HBV DNA after adjustment for age, gender ALT Among HBeAg- lifetime cumulative incidence of HCC for those with clearance of Both HBV DNA and 4.0% HBV DNA only 6.6% Neither 14.2% Liu J, Gut 2014; 63: 1648
7 Cure Access to care Clinical development Antivirals Immunotherapy Discovery Revill & Zoulim, Nature Reviews Gastro & Hepatol 2016; Zoulim, EASL ILC 2016
8 Lack of impact of current antivirals on cccdna plasma membrane Interferon a NUCs Polymerase inhibitors exhaustion high antigen load HBV Filament HBV Sphere HBV Filament ~1 g/ml HBV Filament HBV Sphere ~100 g/ml HBV Sphere ~1 HBV g/ml Virion ~1 g/ml HBV ~100 Filament g/ml ~100 HBV g/ml Sphere HBV Filament ~1 g/ml HBV Filament HBV Sphere ~100 g/ml HBV Sphere ~1 g/ml PD-1 ~1 g/ml ~100 g/ml ~100 g/ml M COPY M HBV Filament M HBV Sphere ~10 COPY ng/ml ~1 g/ml HBV Filament HBV Sphere ~100 g/ml M HBV Filament HBV M Sphere HBV Filament ~1 g/ml HBV COPY HBV Filament HBV Sphere Sphere ~100 g/ml M ~1 g/ml ~10 COPY ng/ml ~1 g/ml ~100 g/ml COPY ~1 g/ml ~100 g/ml ~100 g/ml COPY M M M COPY HBV Filament M HBV M Sphere ~10 COPY ng/ml COPY ~1 g/ml ~100 g/ml M CD8+ T cell Dysfunctional T-cell response B cell Insufficient B-cell response Levrero et al, Current Opinion Virology, 2016
9 The main targets & drug discovery efforts plasma Entry inhibitors membrane RNA interference Targeting cccdna CpAMs Capsid inhibitors NUCs Polymerase inhibitors Inhibitors of release exhaustion high antigen load HBV Filament HBV Sphere Virion HBV Filament HBVHBV Filament~1 g/ml HBV Sphere ~100 g/ml HBV Sphere HBV Virion HBV Filament Sphere ~1 g/ml ~100HBV g/ml ~1 g/ml ~100 g/ml HBV Virion HBV Filament HBV Filament~1 g/ml HBV Sphere ~100 g/ml HBV Sphere ~1 g/ml ~100 g/ml ~1 g/ml ~100M g/ml COPY PD-1 COPY M M HBV Virion COPY HBV Filament HBV Sphere M COPY HBV Sphere COPY COPY HBV Filament ~10 ng/ml ~1 g/ml ~100 g/ml HBV Filament HBVHBV Virion HBV Sphere M ~100 g/mlfilament Filament HBVCOPY Sphere ~1 g/ml HBV Virion HBV HBV Sphere COPY ~1 g/ml g/ml g/ml ~1 g/ml ~100 ~10COPY ng/ml ~1 g/ml~100 ~100 g/ml COPY Immune modulation COPY ~10 ng/ml M M COPY M M HBV Filament HBV Sphere COPY ~1 g/ml ~100 g/ml Toll-like receptors agonists Anti-PD-1 mab Vaccine therapy CD8+ T cell M M M Dysfunctional T-cell response B cell Insufficient B-cell response Revill & Zoulim, Nature Reviews Gastro & Hepatol 2016 ; Levrero et al, Current Opinion Virology, 2016
10 AASLD/EASL HBV Treatment Endpoints Workshop: From Discovery to Regulatory Approval September 8-9, 2016, in Alexandria, VA. Chairs: A. Lok, F. Zoulim, G Dusheiko, M Ghany The introduction of novel compounds for chronic hepatitis B necessitates: 1) a standardized appraisal of the efficacy and safety of these treatments, 2) definitions of new or additional endpoints to inform clinical trials. To move the field forward, and to expedite the pathway from discovery to regulatory approval, a workshop with key stake holders was held in September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials aimed at hepatitis B cure. Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
11 HBV DNA change from baseline (log 10 c/ml) SERUM Definition of cure Therapy Partial Cure Functional Cure +/- Anti-HBsAb HBVDNA Time Sterilizing Cure LIVER cccdna Complete Cure Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
12 Virologic Cure vs. Liver (Clinical) Cure Partial Cure +, HBV DNA UD cccdna+, integrated HBV DNA+ Decreased necroinflammation Fibrosis persists HCC risk persists Functional Cure -, HBV DNA UD cccdna+, integrated HBV DNA+? Sterilizing Cure -, anti-hbs+, HBV DNA UD cccdna & integrated HBV DNA eliminated Regression of fibrosis HCC risk decreases Restoration of liver to normal HCC risk eliminated?
13 Definition of cure The vast majority (87.9%) of survey respondents selected functional cure (sustained loss) as the goal for new HBV therapies. Advantages: easy to assess, associated with improved clinical outcomes & lower rates of disease reactivation, and once achieved, no further requirement for therapy. Less consensus regarding the necessity of achieving anti-hbs seroconversion Discussion: is elimination or silencing of cccdna a mandatory criterion for functional cure? uncertainties whether new therapies in development can silence or clear cccdna, as well as pragmatic difficulties in measuring cccdna. Partial cure: acceptable intermediary step toward functional cure (more achievable in the short-term, reduction in clinical outcomes, and could expedite drug development). Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
14 Durability of Loss in Patients Treated with NUC ± PEG-IFN 74 patients with loss during NUC +/- PEG-IFN treatment All With anti-hbs Without anti-hbs >95% durable if loss confirmed 24 weeks apart, seroconversion to anti-hbs not important 0 Yes Yes No No loss confirmed 24 weeks apart Chan H, EASL 2017
15 Efficacy endpoints for clinical trials The use of a biochemical endpoint is problematic because of the lack of a standardized definition of normal ALT. With increasing prevalence of obesity and non-alcoholic fatty liver disease, failure to normalize ALT may not necessarily indicate ongoing liver inflammation induced by HBV. Non-invasive assessments of liver fibrosis have replaced liver biopsies in assessing liver disease in clinical practice and a histological endpoint would no longer be practical or necessary for assessing functional cure. Liver biopsies may be required in proof-of-concept studies to confirm a novel mode of action and/or to validate noninvasive surrogate markers of antiviral activity. Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
16 Efficacy endpoints: clearance of For both antiviral and immune modulatory therapy trials, suppression of serum HBV DNA to undetectable and loss of were ranked as the most important primary efficacy endpoint for phase 2 and phase 3 trials No consensus whether the kinetics of decline in level can predict ultimate loss The most appropriate time to assess the primary efficacy endpoint for phase 3 trials of novel antiviral or immune modulatory therapies should be month 6 post-treatment, i.e. durable response For Phase 2 studies: depends on the MoA of the drug Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
17 Diagnostic assays for new markers to determine therapeutic efficacy There was consensus on the need for standardized assays to provide mechanistic insights into the effects of novel antiviral or immune modulatory agents and to have new surrogate markers to assess HBV cure Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
18 Dane particles cir HBV-RNAs q HBcrAg Nucleus Cytoplasm Extracellular / serum NUC cccdna drug filament CpAM Subgenomic RNAs pgrna sphere HBeAg HBV RNA particles DNA free particles Dane particles Rc-DNA cccdna Allweiss et al, ANRS-DZIF-ICE-HBV consortium For cccdna standardization pgrna Encapsidated pgrna Subgenomic RNAs Exosomes Testoni, Levrero & Zoulim, Seminars Liver Dis 2017
19 Need for standardized clinical immunology assays Goals of Tx Restoration of T cell activity Restoration of B cell functions Boosting innate immunty Clinical assays needed for: Phenotypic characterization of patients Monitoring of immune activity of novel Tx ICE-HBV immunology working group Testoni and Zoulim, Hepatology 2015
20 Assessment of safety and stopping rules The remarkable safety profile of current NAs imposes a stringent requirement for the safety of new HBV therapies. A unique concern in the development of hepatitis B therapies is the risk of severe hepatitis flares, which can result in hepatic decompensation and death. The U.S. FDA has explicit recommendations on managing drug induced liver injury; however, these recommendations do not apply to patients with underlying liver disease Transient hepatitis flares are not always harmful and may portend immune clearance of infected hepatocytes Severe flares: accompanied by increase in bilirubin or prothrombin time and flares in patients with cirrhosis Any death or liver transplantation, hepatic decompensation, irreversible autoimmunity, or incidence of severe hepatitis flare in >5% of patients could prompt a halt Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
21 Design of clinical trials for HBV cure Combination of antiviral and immune modulatory therapies most likely needed. Antiviral activity and safety of individual new agents used as monotherapy, and drug interactions should be first established before progressing to combination therapy trials. However, demonstration of efficacy as a monotherapy need not be required. Randomized controlled trials needed to establish efficacy (heterogeneity of the natural course of CHB). Trials should aim to demonstrate superiority of the investigational therapy Initially conduct trials in treatment-naïve HBeAg-(+) patients with active disease or in virally suppressed patients. Proof of principle and safety to be established first in patients without cirrhosis. Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
22 Summary and recommendations A functional cure (sustained loss of with or without anti-hbs seroconversion) after a finite course of novel therapies in a higher proportion of patients than currently achieved with existing treatments, is an attainable goal. Need for surrogate markers for cure to assist clinical trials Limited proof-of-concept monotherapy studies to evaluate safety and antiviral activity should be conducted prior to proceeding to combination therapy. The safety of any new curative therapies will be paramount given the excellent safety of currently approved NAs. Lok et al, Hepatitis B Cure: From Discovery to Regulatory Approval; Hepatology / J Hepatol joint publication; 2017
23 HBV cure: An attainable goal within the next decade! Collaboration between Academia, Industry, Regulatory Agencies and Stakeholders International HBV cure programs
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHBV Cure Definition and New Drugs in Development
HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada
More informationWhy do we need new HBV treatment and what is our definition for cure?
Why do we need new HBV treatment and what is our definition for cure? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University
More informationHBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationHBV Cure Overview of Viral and Immune Targets
HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationEffects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB)
Effects of (SB9200) Therapy on Immune Responses Patients with Chronic Hepatitis B (CHB) Renae Walsh 1, Rachel Hammond 1, Kathy Jackson 1, Ros Edwards 1, Chelsea Macfarlane 2, Radhakrishnan P. Iyer 2, Man
More informationThe HBV pipeline and what the SIG can offer
The HBV pipeline and what the SIG can offer Current treatments and definition of cure Where can we get to with current therapies? Special interest group possibilities Where are we headed with HBV cure
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationHepatitis B: Clinical Relevance of HBV cccdna
Hepatitis B: Clinical Relevance of HBV cccdna Fabien Zoulim Hepatology Department, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Lyon University, France What is cccdna? Covalently
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationNovel targets for HBV therapy
VHPB Meeting Hot Topics in Prevention and Control of Viral Hepatitits Lisbon, 15-16th March 2018 Novel targets for HBV therapy Barbara Testoni, PhD Cancer Research Center of Lyon INSERM UMR1052, CNRS 5286
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHBV Treatment Pipeline: Prospects for a Cure. Marion Peters, MD UCSF San Francisco, CA
HBV Treatment Pipeline: Prospects for a Cure Marion Peters, MD UCSF San Francisco, CA HBV Control Inflammatory: normalize serum ALT, biopsy Virologic: decrease HBV DNA Immune: seroconversion HBeAg to anti-hbe
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationIs There a Best Direct Acting Antiviral Agent for HBV?
Is There a Best Direct Acting Antiviral Agent for HBV? Fabien Zoulim Hepatology Department, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Lyon University, France What targets for
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationRevisiting HBV biology: perspective for cure
Revisiting HBV biology: perspective for cure Fabien Zoulim Hepatology Department, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Lyon University, France What do we want to achieve?
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationNeed for long-term evaluation of therapy in Chronic Hepatitis B
Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationUnderstanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development
Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationHepatitis B (and D) Cure Strategies: How far are we?
Hepatitis B (and D) Cure Strategies: How far are we? Heiner Wedemeyer Dept. of Gastroenterology and Hepatology Essen University Hospital International Hepatitis E Symposium February 14-16, 2019 H. Wedemeyer
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationManagement of HBV infection between Specialist and General Practitioners
13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationCHRONIC HEPATITIS B VIRUS Prospects for Cure
VIRAL HEPATITIS and CO-INFECTION with HIV Bucharest, Romania, 6-7 October, 2016 CHRONIC HEPATITIS B VIRUS Prospects for Cure Patrick T. F. Kennedy Reader in Hepatology & Consultant Hepatologist Blizard
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationThe International Coalition to Eliminate Hepatitis B.
The International Coalition to Eliminate Hepatitis B. HBV is currently incurable However functional cure (HBsAg seroclearance) is observed in a small number of patients, either spontaneously or in the
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationby author Novel approaches towards HBV cure
Jörg Petersen Liver Unit IFI Institute at Asklepios Klinik St. Georg University of Hamburg Germany email: petersen@ifi-medizin.de Novel approaches towards HBV cure New horizons in Hepatitis B,D, and E,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationMF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9
SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHepatitis D. Challenges in 2018
Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationInarigivir: A novel RIG-I agonist for chronic hepatitis B
: A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More information23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016
23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016 Λεηηοσργηθή θαη Ιοιογηθή Ιαζε ηες Χρολίας Ηπαηίηηδας Β: Παρόλ θαη Μέιιολ Σηέθαλος Χαηδεγηάλλες Οκόηηκος Καζεγεηής
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationGUIDELINE. South African guideline for the management of chronic hepatitis B: 2013
South African guideline for the management of chronic hepatitis B: 2013 C W N Spearman, 1 MB ChB, FCP (SA), MMed, PhD; M W Sonderup, 1,2 MB ChB, BPharm, FCP (SA); J F Botha, 2,3 MB ChB, FCP (SA); S W van
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationSERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca
SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca Louis Jansen 1,2, Andrew Vaillant 3, Karel van Dort 1, Femke Stelma 1,2, Neeltje
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationRNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
More informationEASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver Summary Hepatitis B virus (HBV) infection remains a global public
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationNew (Virological) Tools for Testing and Monitoring Hepatitis B and C
New (Virological) Tools for Testing and Monitoring Hepatitis B and C Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty
More informationHBV Forum pre-easl 2018
HBV Roadmap Update from Recent and EASL Presentations HBV Forum pre-easl 2018 Robert G Gish MD Adjunct Professor Stanford University Medical Director HB Foundation See robertgish.com Disclosures Introduction
More information